OPEN MARKET CONSULTATION COMPANIES LOOKING FOR CONSORTIUM WORKSHOPS FAQ
 
In the pursuit of finding holistic solutions that will make the lives of chronic patients better and enable them to self-manage their diseases, EMPATTICS is looking for input from companies and consortia.

Join the dialogue

By joining the dialogue you will get an opportunity to learn about the common challenges and the latest developments within the chronic disease care in the Buyers’ regions. You will have a chance to network and to have an input in the future of chronic disease treatment, requirements for ICT tools and public procurement tender materials.

You can do so by:

• Meeting EMPATTICS at various events throughout European Union.
• Expressing your opinion through Open Market Consultation.
• Sending us your questions directly.

Please check our website or subscribe to the newsletters to learn more

Apply to the pre-commercial procurement tender

By participating in the pre-commercial tender you will have the chance to receive budget for Research and Development (R&D) activities.

The Buyers within EMPATTICS will have an open call for buying several R&D services for modular ICT tools that are based on the principles of patient empowerment and self-management, where each module can be adapted to different chronic diseases by the Buyers.

The tools should act as platforms to:

• Increase the awareness and knowledge about treatment adherence.
• Provide valuable information for self-care management of patient diseases.
• Help patients to develop healthy adaptive behaviors to change the problematic ones.
• Facilitate the communication between patients and health professionals.

The tender will be based on the principles of Pre-Commercial Procurement (PCP). It is a form of procurement of several R&D services for innovative solutions in parallel before those are commercially available on the market through a 3-phase scheme.

In practice that means that:

• Based on the open market competition principles, several companies will be awarded with a contract to provide R&D services.
• The number of competing R&D providers will be reduced after each PCP phase subsequent to intermediate evaluations.
• The budget will gradually increase throughout the PCP phases.

Benefits

SHARED RISKS AND BENEFITS
The PCP setup lets the companies to share the risks and the benefits associated with product development with the Buyers.

WORKING TOWARDS COMMERCIALIZATION
While for large enterprises the financial contribution might be insignificant, SMEs can benefit from PCP in order to take their ideas one step closer to commercialization. EMPATTICS will not own Intellectual Property Rights.

ACCESS TO EXPERTISE, TESTING SITES AND MARKETS
As the Buyers are from different European countries, the companies can get insights into several markets. The companies will get access to the knowledge, clinicians, patients and the infrastructure in the Buyers’ regions.